MX360880B - Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3il)- 3,4-dihidropirazino [2,3-b]pirazin-2(1h)-ona para usarse en el tratamiento de cancer de mama triple negativo. - Google Patents

Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3il)- 3,4-dihidropirazino [2,3-b]pirazin-2(1h)-ona para usarse en el tratamiento de cancer de mama triple negativo.

Info

Publication number
MX360880B
MX360880B MX2014011118A MX2014011118A MX360880B MX 360880 B MX360880 B MX 360880B MX 2014011118 A MX2014011118 A MX 2014011118A MX 2014011118 A MX2014011118 A MX 2014011118A MX 360880 B MX360880 B MX 360880B
Authority
MX
Mexico
Prior art keywords
tor kinase
cancer
treatment
breast cancer
kinase inhibitors
Prior art date
Application number
MX2014011118A
Other languages
English (en)
Other versions
MX2014011118A (es
Inventor
K Narla Rama
Xu Shuichan
Mae Hege Kristen
Raymon Heather
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of MX2014011118A publication Critical patent/MX2014011118A/es
Publication of MX360880B publication Critical patent/MX360880B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente métodos para tratar o prevenir el cáncer de mama triple negativo o cáncer de mama positivo del receptor de hormona, que comprende administrar una cantidad efectiva de un inhibidor de TOR cinasa a un paciente que tiene cáncer de mama triple negativo o cáncer de mama positivo del receptor de hormona.
MX2014011118A 2012-03-15 2013-03-14 Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3il)- 3,4-dihidropirazino [2,3-b]pirazin-2(1h)-ona para usarse en el tratamiento de cancer de mama triple negativo. MX360880B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611374P 2012-03-15 2012-03-15
US201261715331P 2012-10-18 2012-10-18
PCT/US2013/031185 WO2013138553A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014011118A MX2014011118A (es) 2015-04-08
MX360880B true MX360880B (es) 2018-11-21

Family

ID=48014333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011118A MX360880B (es) 2012-03-15 2013-03-14 Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3il)- 3,4-dihidropirazino [2,3-b]pirazin-2(1h)-ona para usarse en el tratamiento de cancer de mama triple negativo.

Country Status (20)

Country Link
US (2) US20130245027A1 (es)
EP (1) EP2825169B1 (es)
JP (2) JP2015511963A (es)
KR (1) KR102057359B1 (es)
CN (1) CN104271139A (es)
AU (1) AU2013202993B2 (es)
BR (1) BR112014022707A2 (es)
CA (1) CA2867348A1 (es)
ES (1) ES2678250T3 (es)
HK (1) HK1201753A1 (es)
IL (1) IL234641B (es)
MX (1) MX360880B (es)
MY (1) MY178012A (es)
NI (1) NI201400112A (es)
NZ (1) NZ628407A (es)
PH (1) PH12014502046A1 (es)
SG (1) SG11201405724RA (es)
TW (1) TWI635862B (es)
WO (1) WO2013138553A1 (es)
ZA (1) ZA201406701B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
WO2014172423A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
EP4218763A1 (en) 2013-04-17 2023-08-02 Signal Pharmaceuticals, LLC 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for treating glioblastoma multiforme
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
TWI631949B (zh) * 2013-04-17 2018-08-11 標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
WO2014172426A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986319A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
BR112019027402A2 (pt) 2017-06-22 2020-07-07 Celgene Corporation tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
CN112933088B (zh) * 2021-02-03 2022-02-22 南华大学附属第一医院 Y041-5921在制备抗肿瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2631003T3 (es) 2006-10-19 2017-08-25 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
CA2666624C (en) * 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
US20090258096A1 (en) * 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer Methods Employing Extracts of Gleditsia sinensis Lam
EP2320894B1 (en) * 2008-08-20 2016-12-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP2493472B1 (en) 2009-10-26 2016-12-07 Signal Pharmaceuticals, LLC Methods of synthesis and purification of heteroaryl compounds

Also Published As

Publication number Publication date
PH12014502046B1 (en) 2014-12-10
JP6470820B2 (ja) 2019-02-13
EP2825169B1 (en) 2018-05-09
BR112014022707A2 (pt) 2020-10-27
CN104271139A (zh) 2015-01-07
NI201400112A (es) 2015-01-15
EP2825169A1 (en) 2015-01-21
WO2013138553A1 (en) 2013-09-19
TW201343165A (zh) 2013-11-01
ZA201406701B (en) 2016-05-25
MY178012A (en) 2020-09-29
US20230338370A1 (en) 2023-10-26
US20130245027A1 (en) 2013-09-19
CA2867348A1 (en) 2013-09-19
AU2013202993B2 (en) 2015-09-03
JP2015511963A (ja) 2015-04-23
SG11201405724RA (en) 2014-10-30
IL234641B (en) 2020-04-30
IL234641A0 (en) 2014-11-30
NZ628407A (en) 2016-04-29
MX2014011118A (es) 2015-04-08
HK1201753A1 (en) 2015-09-11
KR102057359B1 (ko) 2019-12-18
TWI635862B (zh) 2018-09-21
AU2013202993A1 (en) 2013-10-03
ES2678250T3 (es) 2018-08-09
PH12014502046A1 (en) 2014-12-10
JP2018052963A (ja) 2018-04-05
KR20140138951A (ko) 2014-12-04

Similar Documents

Publication Publication Date Title
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
MX357833B (es) Tratamiento del cancer con inhibidores de tor cinasa.
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
PH12014502029B1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502047B1 (en) Treatment of cancer with tor kinase inhibitors
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
SA515370011B1 (ar) طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين
MX2015014590A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы

Legal Events

Date Code Title Description
FG Grant or registration